SA PRO
Free Account
Themes
Bicycle Therapeutics plcBCYCNASDAQ
Loading
OverviewIntelligenceChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating
Buy
20 analysts·High coverage
85%
Rating Distribution
Strong Buy
00%
Buy
1785%
Hold
315%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 96% higher.

Bear Case
$10.00
+79%
Consensus
$11.00
+96%
Bull Case
$12.00
+114%
Price Range20 analysts
Low
Consensus
High
$10.00
$12.00
Current Target
Current Price
$5.60
Upside to Target
$5.40

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 24, 2025Truist Financial
Bicycle Therapeutics initiated with a Hold at Truist
Target:$10.00
+58.2%from $6.32
Oct 31, 2025JMP Securities
Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP
Target:$12.00
+37.0%from $8.76
Oct 31, 2025RBC Capital
RBC downgrades Bicycle Therapeutics on slow pipeline progress
Target:$11.00
+25.6%from $8.76
Aug 11, 2025RBC Capital
Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital
Target:$27.00
+255.8%from $7.59
May 5, 2025Morgan Stanley
Bicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley
Target:$17.00
+87.6%from $9.06
Dec 18, 2024JMP Securities
Bicycle Therapeutics price target lowered to $26 from $32 at JMP Securities
Target:$26.00
+69.7%from $15.32
Oct 24, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)
Target:$48.00
+89.6%from $25.32
Oct 24, 2024B.Riley Financial
B.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC)
Target:$28.00
+10.6%from $25.32
Sep 16, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
Target:$55.00
+103.6%from $27.02
Oct 7, 2021Roth Capital
Bicycle Therapeutics (BCYC) PT Raised to $65 at Roth Capital
Target:$65.00
+33.5%from $48.69
Oct 7, 2021Piper Sandler
Bicycle Therapeutics price target raised to $76 from $46 at Piper Sandler
Target:$76.00
+56.1%from $48.69

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance